Labcorp Holdings Inc. (NYSE: LH) Stock Competitors & Peer Comparison
See LH's competitors and their performance on the NYSE and across the wider stock market.
Peer Comparison Table: Medical - Diagnostics & Research Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for LH and its NYSE peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| LH | $329.90 | +0.29% | 26.8B | 19.58 | $16.85 | +0.88% |
| DHR-PB | $1,261.26 | -0.78% | 916.8B | 146.01 | $8.64 | +0.66% |
| TMO | $684.89 | +1.64% | 253.2B | 29.56 | $23.16 | +0.27% |
| DHR | $232.97 | +1.07% | 163.8B | 29.19 | $7.98 | +0.66% |
| NTRA | $404.90 | +0.24% | 58.4B | -306.74 | -$1.32 | N/A |
| A | $175.96 | +1.67% | 49.6B | 30.28 | $5.81 | +0.58% |
| IQV | $273.60 | -2.06% | 45B | 22.55 | $12.13 | N/A |
| IDXX | $570.21 | +1.75% | 44.9B | 40.10 | $14.22 | N/A |
| WAT | $455.98 | +0.51% | 44.8B | 33.33 | $13.68 | N/A |
| ILMN | $271.04 | +0.60% | 40.9B | 53.88 | $5.03 | N/A |
Stock Comparison
Danaher Corporation (NYSE: DHR-PB)
LH vs DHR-PB Comparison October 2026
Labcorp Holdings Inc. (NYSE: LH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LH stands at 26.8B. In comparison, DHR-PB has a market cap of 916.8B. Regarding current trading prices, LH is priced at $329.90 on the NYSE, while DHR-PB trades at $1,261.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LH currently has a P/E ratio of 19.58, whereas DHR-PB's P/E ratio is 146.01. In terms of profitability, LH's ROE is +0.12%, compared to DHR-PB's ROE of +0.08%. Regarding short-term risk, LH is more volatile compared to DHR-PB. This indicates higher risk in terms of short-term price fluctuations for LH.Check DHR-PB's competition here
Thermo Fisher Scientific Inc. (NYSE: TMO)
LH vs TMO Comparison October 2026
Labcorp Holdings Inc. (NYSE: LH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LH stands at 26.8B. In comparison, TMO has a market cap of 253.2B. Regarding current trading prices, LH is priced at $329.90 on the NYSE, while TMO trades at $684.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LH currently has a P/E ratio of 19.58, whereas TMO's P/E ratio is 29.56. In terms of profitability, LH's ROE is +0.12%, compared to TMO's ROE of +0.13%. Regarding short-term risk, LH is less volatile compared to TMO. This indicates lower risk in terms of short-term price fluctuations for LH.Check TMO's competition here
Danaher Corporation (NYSE: DHR)
LH vs DHR Comparison October 2026
Labcorp Holdings Inc. (NYSE: LH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LH stands at 26.8B. In comparison, DHR has a market cap of 163.8B. Regarding current trading prices, LH is priced at $329.90 on the NYSE, while DHR trades at $232.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LH currently has a P/E ratio of 19.58, whereas DHR's P/E ratio is 29.19. In terms of profitability, LH's ROE is +0.12%, compared to DHR's ROE of +0.08%. Regarding short-term risk, LH is less volatile compared to DHR. This indicates lower risk in terms of short-term price fluctuations for LH.Check DHR's competition here
Natera, Inc. (NASDAQ: NTRA)
LH vs NTRA Comparison October 2026
Labcorp Holdings Inc. (NYSE: LH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LH stands at 26.8B. In comparison, NTRA has a market cap of 58.4B. Regarding current trading prices, LH is priced at $329.90 on the NYSE, while NTRA trades at $404.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LH currently has a P/E ratio of 19.58, whereas NTRA's P/E ratio is -306.74. In terms of profitability, LH's ROE is +0.12%, compared to NTRA's ROE of -0.12%. Regarding short-term risk, LH is less volatile compared to NTRA. This indicates lower risk in terms of short-term price fluctuations for LH.Check NTRA's competition here
Agilent Technologies, Inc. (NYSE: A)
LH vs A Comparison October 2026
Labcorp Holdings Inc. (NYSE: LH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LH stands at 26.8B. In comparison, A has a market cap of 49.6B. Regarding current trading prices, LH is priced at $329.90 on the NYSE, while A trades at $175.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LH currently has a P/E ratio of 19.58, whereas A's P/E ratio is 30.28. In terms of profitability, LH's ROE is +0.12%, compared to A's ROE of +0.20%. Regarding short-term risk, LH is less volatile compared to A. This indicates lower risk in terms of short-term price fluctuations for LH.Check A's competition here
IQVIA Holdings Inc. (NYSE: IQV)
LH vs IQV Comparison October 2026
Labcorp Holdings Inc. (NYSE: LH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LH stands at 26.8B. In comparison, IQV has a market cap of 45B. Regarding current trading prices, LH is priced at $329.90 on the NYSE, while IQV trades at $273.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LH currently has a P/E ratio of 19.58, whereas IQV's P/E ratio is 22.55. In terms of profitability, LH's ROE is +0.12%, compared to IQV's ROE of +0.22%. Regarding short-term risk, LH is less volatile compared to IQV. This indicates lower risk in terms of short-term price fluctuations for LH.Check IQV's competition here
IDEXX Laboratories, Inc. (NASDAQ: IDXX)
LH vs IDXX Comparison October 2026
Labcorp Holdings Inc. (NYSE: LH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LH stands at 26.8B. In comparison, IDXX has a market cap of 44.9B. Regarding current trading prices, LH is priced at $329.90 on the NYSE, while IDXX trades at $570.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LH currently has a P/E ratio of 19.58, whereas IDXX's P/E ratio is 40.10. In terms of profitability, LH's ROE is +0.12%, compared to IDXX's ROE of +0.72%. Regarding short-term risk, LH is less volatile compared to IDXX. This indicates lower risk in terms of short-term price fluctuations for LH.Check IDXX's competition here
Waters Corporation (NYSE: WAT)
LH vs WAT Comparison October 2026
Labcorp Holdings Inc. (NYSE: LH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LH stands at 26.8B. In comparison, WAT has a market cap of 44.8B. Regarding current trading prices, LH is priced at $329.90 on the NYSE, while WAT trades at $455.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LH currently has a P/E ratio of 19.58, whereas WAT's P/E ratio is 33.33. In terms of profitability, LH's ROE is +0.12%, compared to WAT's ROE of +0.02%. Regarding short-term risk, LH is less volatile compared to WAT. This indicates lower risk in terms of short-term price fluctuations for LH.Check WAT's competition here
Illumina, Inc. (NASDAQ: ILMN)
LH vs ILMN Comparison October 2026
Labcorp Holdings Inc. (NYSE: LH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LH stands at 26.8B. In comparison, ILMN has a market cap of 40.9B. Regarding current trading prices, LH is priced at $329.90 on the NYSE, while ILMN trades at $271.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LH currently has a P/E ratio of 19.58, whereas ILMN's P/E ratio is 53.88. In terms of profitability, LH's ROE is +0.12%, compared to ILMN's ROE of +0.31%. Regarding short-term risk, LH is less volatile compared to ILMN. This indicates lower risk in terms of short-term price fluctuations for LH.Check ILMN's competition here
Mettler-Toledo International Inc. (NYSE: MTD)
LH vs MTD Comparison October 2026
Labcorp Holdings Inc. (NYSE: LH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LH stands at 26.8B. In comparison, MTD has a market cap of 33.5B. Regarding current trading prices, LH is priced at $329.90 on the NYSE, while MTD trades at $1,669.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LH currently has a P/E ratio of 19.58, whereas MTD's P/E ratio is 38.40. In terms of profitability, LH's ROE is +0.12%, compared to MTD's ROE of -12.00%. Regarding short-term risk, LH is more volatile compared to MTD. This indicates higher risk in terms of short-term price fluctuations for LH.Check MTD's competition here
Quest Diagnostics Incorporated (NYSE: DGX)
LH vs DGX Comparison October 2026
Labcorp Holdings Inc. (NYSE: LH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LH stands at 26.8B. In comparison, DGX has a market cap of 26.8B. Regarding current trading prices, LH is priced at $329.90 on the NYSE, while DGX trades at $242.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LH currently has a P/E ratio of 19.58, whereas DGX's P/E ratio is 23.96. In terms of profitability, LH's ROE is +0.12%, compared to DGX's ROE of +0.15%. Regarding short-term risk, LH is more volatile compared to DGX. This indicates higher risk in terms of short-term price fluctuations for LH.Check DGX's competition here
Guardant Health, Inc. (NASDAQ: GH)
LH vs GH Comparison October 2026
Labcorp Holdings Inc. (NYSE: LH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LH stands at 26.8B. In comparison, GH has a market cap of 23.2B. Regarding current trading prices, LH is priced at $329.90 on the NYSE, while GH trades at $173.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LH currently has a P/E ratio of 19.58, whereas GH's P/E ratio is -49.64. In terms of profitability, LH's ROE is +0.12%, compared to GH's ROE of +2.11%. Regarding short-term risk, LH is less volatile compared to GH. This indicates lower risk in terms of short-term price fluctuations for LH.Check GH's competition here
Exact Sciences Corporation (NASDAQ: EXAS)
LH vs EXAS Comparison October 2026
Labcorp Holdings Inc. (NYSE: LH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LH stands at 26.8B. In comparison, EXAS has a market cap of 20B. Regarding current trading prices, LH is priced at $329.90 on the NYSE, while EXAS trades at $104.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LH currently has a P/E ratio of 19.58, whereas EXAS's P/E ratio is -95.37. In terms of profitability, LH's ROE is +0.12%, compared to EXAS's ROE of -0.04%. Regarding short-term risk, LH is more volatile compared to EXAS. This indicates higher risk in terms of short-term price fluctuations for LH.Check EXAS's competition here
Medpace Holdings, Inc. (NASDAQ: MEDP)
LH vs MEDP Comparison October 2026
Labcorp Holdings Inc. (NYSE: LH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LH stands at 26.8B. In comparison, MEDP has a market cap of 18.9B. Regarding current trading prices, LH is priced at $329.90 on the NYSE, while MEDP trades at $676.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LH currently has a P/E ratio of 19.58, whereas MEDP's P/E ratio is 39.67. In terms of profitability, LH's ROE is +0.12%, compared to MEDP's ROE of +1.00%. Regarding short-term risk, LH is less volatile compared to MEDP. This indicates lower risk in terms of short-term price fluctuations for LH.Check MEDP's competition here
Revvity, Inc. (NYSE: RVTY)
LH vs RVTY Comparison October 2026
Labcorp Holdings Inc. (NYSE: LH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LH stands at 26.8B. In comparison, RVTY has a market cap of 17.9B. Regarding current trading prices, LH is priced at $329.90 on the NYSE, while RVTY trades at $160.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LH currently has a P/E ratio of 19.58, whereas RVTY's P/E ratio is 29.98. In terms of profitability, LH's ROE is +0.12%, compared to RVTY's ROE of +0.03%. Regarding short-term risk, LH is less volatile compared to RVTY. This indicates lower risk in terms of short-term price fluctuations for LH.Check RVTY's competition here
Charles River Laboratories International, Inc. (NYSE: CRL)
LH vs CRL Comparison October 2026
Labcorp Holdings Inc. (NYSE: LH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LH stands at 26.8B. In comparison, CRL has a market cap of 17.2B. Regarding current trading prices, LH is priced at $329.90 on the NYSE, while CRL trades at $357.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LH currently has a P/E ratio of 19.58, whereas CRL's P/E ratio is 36.07. In terms of profitability, LH's ROE is +0.12%, compared to CRL's ROE of -0.08%. Regarding short-term risk, LH is less volatile compared to CRL. This indicates lower risk in terms of short-term price fluctuations for LH.Check CRL's competition here
Illumina, Inc. Common Stock Ex-distribution When-Issued (NASDAQ: ILMNV)
LH vs ILMNV Comparison October 2026
Labcorp Holdings Inc. (NYSE: LH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LH stands at 26.8B. In comparison, ILMNV has a market cap of 17B. Regarding current trading prices, LH is priced at $329.90 on the NYSE, while ILMNV trades at $107.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LH currently has a P/E ratio of 19.58, whereas ILMNV's P/E ratio is N/A. In terms of profitability, LH's ROE is +0.12%, compared to ILMNV's ROE of N/A. Regarding short-term risk, LH is more volatile compared to ILMNV. This indicates higher risk in terms of short-term price fluctuations for LH.Check ILMNV's competition here
PerkinElmer, Inc. (NYSE: PKI)
LH vs PKI Comparison October 2026
Labcorp Holdings Inc. (NYSE: LH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LH stands at 26.8B. In comparison, PKI has a market cap of 14.5B. Regarding current trading prices, LH is priced at $329.90 on the NYSE, while PKI trades at $115.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LH currently has a P/E ratio of 19.58, whereas PKI's P/E ratio is 41.45. In terms of profitability, LH's ROE is +0.12%, compared to PKI's ROE of +0.03%. Regarding short-term risk, LH is less volatile compared to PKI. This indicates lower risk in terms of short-term price fluctuations for LH.Check PKI's competition here
ICON Public Limited Company (NASDAQ: ICLR)
LH vs ICLR Comparison October 2026
Labcorp Holdings Inc. (NYSE: LH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LH stands at 26.8B. In comparison, ICLR has a market cap of 14.2B. Regarding current trading prices, LH is priced at $329.90 on the NYSE, while ICLR trades at $183.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LH currently has a P/E ratio of 19.58, whereas ICLR's P/E ratio is 14.99. In terms of profitability, LH's ROE is +0.12%, compared to ICLR's ROE of +0.04%. Regarding short-term risk, LH is less volatile compared to ICLR. This indicates lower risk in terms of short-term price fluctuations for LH.Check ICLR's competition here
Qiagen N.V. (NYSE: QGEN)
LH vs QGEN Comparison October 2026
Labcorp Holdings Inc. (NYSE: LH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LH stands at 26.8B. In comparison, QGEN has a market cap of 10.4B. Regarding current trading prices, LH is priced at $329.90 on the NYSE, while QGEN trades at $50.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LH currently has a P/E ratio of 19.58, whereas QGEN's P/E ratio is 20.81. In terms of profitability, LH's ROE is +0.12%, compared to QGEN's ROE of +0.12%. Regarding short-term risk, LH is more volatile compared to QGEN. This indicates higher risk in terms of short-term price fluctuations for LH.Check QGEN's competition here
GRAIL Inc. (NASDAQ: GRAL)
LH vs GRAL Comparison October 2026
Labcorp Holdings Inc. (NYSE: LH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LH stands at 26.8B. In comparison, GRAL has a market cap of 6.2B. Regarding current trading prices, LH is priced at $329.90 on the NYSE, while GRAL trades at $139.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LH currently has a P/E ratio of 19.58, whereas GRAL's P/E ratio is -14.35. In terms of profitability, LH's ROE is +0.12%, compared to GRAL's ROE of -0.16%. Regarding short-term risk, LH is less volatile compared to GRAL. This indicates lower risk in terms of short-term price fluctuations for LH.Check GRAL's competition here
RadNet, Inc. (NASDAQ: RDNT)
LH vs RDNT Comparison October 2026
Labcorp Holdings Inc. (NYSE: LH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LH stands at 26.8B. In comparison, RDNT has a market cap of 5.5B. Regarding current trading prices, LH is priced at $329.90 on the NYSE, while RDNT trades at $70.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LH currently has a P/E ratio of 19.58, whereas RDNT's P/E ratio is 152.28. In terms of profitability, LH's ROE is +0.12%, compared to RDNT's ROE of -0.02%. Regarding short-term risk, LH is less volatile compared to RDNT. This indicates lower risk in terms of short-term price fluctuations for LH.Check RDNT's competition here
BillionToOne, Inc. (NASDAQ: BLLN)
LH vs BLLN Comparison October 2026
Labcorp Holdings Inc. (NYSE: LH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LH stands at 26.8B. In comparison, BLLN has a market cap of 5.3B. Regarding current trading prices, LH is priced at $329.90 on the NYSE, while BLLN trades at $111.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LH currently has a P/E ratio of 19.58, whereas BLLN's P/E ratio is 159.24. In terms of profitability, LH's ROE is +0.12%, compared to BLLN's ROE of +0.08%. Regarding short-term risk, LH is less volatile compared to BLLN. This indicates lower risk in terms of short-term price fluctuations for LH.Check BLLN's competition here
Sotera Health Company (NASDAQ: SHC)
LH vs SHC Comparison October 2026
Labcorp Holdings Inc. (NYSE: LH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LH stands at 26.8B. In comparison, SHC has a market cap of 5.2B. Regarding current trading prices, LH is priced at $329.90 on the NYSE, while SHC trades at $18.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LH currently has a P/E ratio of 19.58, whereas SHC's P/E ratio is 19.16. In terms of profitability, LH's ROE is +0.12%, compared to SHC's ROE of +0.27%. Regarding short-term risk, LH is less volatile compared to SHC. This indicates lower risk in terms of short-term price fluctuations for LH.Check SHC's competition here
Syneos Health, Inc. (NASDAQ: SYNH)
LH vs SYNH Comparison October 2026
Labcorp Holdings Inc. (NYSE: LH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LH stands at 26.8B. In comparison, SYNH has a market cap of 4.5B. Regarding current trading prices, LH is priced at $329.90 on the NYSE, while SYNH trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LH currently has a P/E ratio of 19.58, whereas SYNH's P/E ratio is 61.40. In terms of profitability, LH's ROE is +0.12%, compared to SYNH's ROE of +0.08%. Regarding short-term risk, LH is more volatile compared to SYNH. This indicates higher risk in terms of short-term price fluctuations for LH.Check SYNH's competition here
Veracyte, Inc. (NASDAQ: VCYT)
LH vs VCYT Comparison October 2026
Labcorp Holdings Inc. (NYSE: LH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LH stands at 26.8B. In comparison, VCYT has a market cap of 3.9B. Regarding current trading prices, LH is priced at $329.90 on the NYSE, while VCYT trades at $48.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LH currently has a P/E ratio of 19.58, whereas VCYT's P/E ratio is 24.10. In terms of profitability, LH's ROE is +0.12%, compared to VCYT's ROE of +0.09%. Regarding short-term risk, LH is less volatile compared to VCYT. This indicates lower risk in terms of short-term price fluctuations for LH.Check VCYT's competition here
CareDx, Inc (NASDAQ: CDNA)
LH vs CDNA Comparison October 2026
Labcorp Holdings Inc. (NYSE: LH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LH stands at 26.8B. In comparison, CDNA has a market cap of 3.6B. Regarding current trading prices, LH is priced at $329.90 on the NYSE, while CDNA trades at $69.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LH currently has a P/E ratio of 19.58, whereas CDNA's P/E ratio is 82.26. In terms of profitability, LH's ROE is +0.12%, compared to CDNA's ROE of +0.33%. Regarding short-term risk, LH is less volatile compared to CDNA. This indicates lower risk in terms of short-term price fluctuations for LH.Check CDNA's competition here
Olink Holding AB (publ) (NASDAQ: OLK)
LH vs OLK Comparison October 2026
Labcorp Holdings Inc. (NYSE: LH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LH stands at 26.8B. In comparison, OLK has a market cap of 3.2B. Regarding current trading prices, LH is priced at $329.90 on the NYSE, while OLK trades at $26.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LH currently has a P/E ratio of 19.58, whereas OLK's P/E ratio is -96.59. In terms of profitability, LH's ROE is +0.12%, compared to OLK's ROE of -0.07%. Regarding short-term risk, LH is more volatile compared to OLK. This indicates higher risk in terms of short-term price fluctuations for LH.Check OLK's competition here
NeoGenomics, Inc. (NASDAQ: NEO)
LH vs NEO Comparison October 2026
Labcorp Holdings Inc. (NYSE: LH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LH stands at 26.8B. In comparison, NEO has a market cap of 2.2B. Regarding current trading prices, LH is priced at $329.90 on the NYSE, while NEO trades at $16.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LH currently has a P/E ratio of 19.58, whereas NEO's P/E ratio is 128.38. In terms of profitability, LH's ROE is +0.12%, compared to NEO's ROE of -0.06%. Regarding short-term risk, LH is less volatile compared to NEO. This indicates lower risk in terms of short-term price fluctuations for LH.Check NEO's competition here
GeneDx Holdings Corp. (NASDAQ: WGS)
LH vs WGS Comparison October 2026
Labcorp Holdings Inc. (NYSE: LH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LH stands at 26.8B. In comparison, WGS has a market cap of 1.8B. Regarding current trading prices, LH is priced at $329.90 on the NYSE, while WGS trades at $61.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LH currently has a P/E ratio of 19.58, whereas WGS's P/E ratio is 170.17. In terms of profitability, LH's ROE is +0.12%, compared to WGS's ROE of -0.39%. Regarding short-term risk, LH is less volatile compared to WGS. This indicates lower risk in terms of short-term price fluctuations for LH.Check WGS's competition here
Personalis, Inc. (NASDAQ: PSNL)
LH vs PSNL Comparison October 2026
Labcorp Holdings Inc. (NYSE: LH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LH stands at 26.8B. In comparison, PSNL has a market cap of 1.7B. Regarding current trading prices, LH is priced at $329.90 on the NYSE, while PSNL trades at $15.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LH currently has a P/E ratio of 19.58, whereas PSNL's P/E ratio is -14.57. In terms of profitability, LH's ROE is +0.12%, compared to PSNL's ROE of -0.46%. Regarding short-term risk, LH is more volatile compared to PSNL. This indicates higher risk in terms of short-term price fluctuations for LH.Check PSNL's competition here
OPKO Health, Inc. (NASDAQ: OPK)
LH vs OPK Comparison October 2026
Labcorp Holdings Inc. (NYSE: LH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LH stands at 26.8B. In comparison, OPK has a market cap of 1.2B. Regarding current trading prices, LH is priced at $329.90 on the NYSE, while OPK trades at $1.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LH currently has a P/E ratio of 19.58, whereas OPK's P/E ratio is -18.11. In terms of profitability, LH's ROE is +0.12%, compared to OPK's ROE of -0.06%. Regarding short-term risk, LH is less volatile compared to OPK. This indicates lower risk in terms of short-term price fluctuations for LH.Check OPK's competition here
Castle Biosciences, Inc. (NASDAQ: CSTL)
LH vs CSTL Comparison October 2026
Labcorp Holdings Inc. (NYSE: LH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LH stands at 26.8B. In comparison, CSTL has a market cap of 1B. Regarding current trading prices, LH is priced at $329.90 on the NYSE, while CSTL trades at $33.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LH currently has a P/E ratio of 19.58, whereas CSTL's P/E ratio is -50.45. In terms of profitability, LH's ROE is +0.12%, compared to CSTL's ROE of -0.04%. Regarding short-term risk, LH is less volatile compared to CSTL. This indicates lower risk in terms of short-term price fluctuations for LH.Check CSTL's competition here
GRAIL, Inc. Common Stock (NASDAQ: GRALV)
LH vs GRALV Comparison October 2026
Labcorp Holdings Inc. (NYSE: LH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LH stands at 26.8B. In comparison, GRALV has a market cap of 579.4M. Regarding current trading prices, LH is priced at $329.90 on the NYSE, while GRALV trades at $18.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LH currently has a P/E ratio of 19.58, whereas GRALV's P/E ratio is N/A. In terms of profitability, LH's ROE is +0.12%, compared to GRALV's ROE of N/A. Regarding short-term risk, LH is less volatile compared to GRALV. This indicates lower risk in terms of short-term price fluctuations for LH.Check GRALV's competition here
Myriad Genetics, Inc. (NASDAQ: MYGN)
LH vs MYGN Comparison October 2026
Labcorp Holdings Inc. (NYSE: LH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LH stands at 26.8B. In comparison, MYGN has a market cap of 575.8M. Regarding current trading prices, LH is priced at $329.90 on the NYSE, while MYGN trades at $6.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LH currently has a P/E ratio of 19.58, whereas MYGN's P/E ratio is -46.31. In terms of profitability, LH's ROE is +0.12%, compared to MYGN's ROE of -0.33%. Regarding short-term risk, LH is less volatile compared to MYGN. This indicates lower risk in terms of short-term price fluctuations for LH.Check MYGN's competition here
Fulgent Genetics, Inc. (NASDAQ: FLGT)
LH vs FLGT Comparison October 2026
Labcorp Holdings Inc. (NYSE: LH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LH stands at 26.8B. In comparison, FLGT has a market cap of 556.4M. Regarding current trading prices, LH is priced at $329.90 on the NYSE, while FLGT trades at $20.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LH currently has a P/E ratio of 19.58, whereas FLGT's P/E ratio is 2022.00. In terms of profitability, LH's ROE is +0.12%, compared to FLGT's ROE of -0.08%. Regarding short-term risk, LH is less volatile compared to FLGT. This indicates lower risk in terms of short-term price fluctuations for LH.Check FLGT's competition here
Global Cord Blood Corporation (NYSE: CO)
LH vs CO Comparison October 2026
Labcorp Holdings Inc. (NYSE: LH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LH stands at 26.8B. In comparison, CO has a market cap of 400.1M. Regarding current trading prices, LH is priced at $329.90 on the NYSE, while CO trades at $2.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LH currently has a P/E ratio of 19.58, whereas CO's P/E ratio is 5.06. In terms of profitability, LH's ROE is +0.12%, compared to CO's ROE of +0.11%. Regarding short-term risk, LH is less volatile compared to CO. This indicates lower risk in terms of short-term price fluctuations for LH.Check CO's competition here
Standard BioTools Inc. (NASDAQ: FLDM)
LH vs FLDM Comparison October 2026
Labcorp Holdings Inc. (NYSE: LH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LH stands at 26.8B. In comparison, FLDM has a market cap of 294.2M. Regarding current trading prices, LH is priced at $329.90 on the NYSE, while FLDM trades at $3.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LH currently has a P/E ratio of 19.58, whereas FLDM's P/E ratio is -4.74. In terms of profitability, LH's ROE is +0.12%, compared to FLDM's ROE of +0.18%. Regarding short-term risk, LH is less volatile compared to FLDM. This indicates lower risk in terms of short-term price fluctuations for LH.Check FLDM's competition here
Exagen Inc. (NASDAQ: XGN)
LH vs XGN Comparison October 2026
Labcorp Holdings Inc. (NYSE: LH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LH stands at 26.8B. In comparison, XGN has a market cap of 181M. Regarding current trading prices, LH is priced at $329.90 on the NYSE, while XGN trades at $7.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LH currently has a P/E ratio of 19.58, whereas XGN's P/E ratio is -9.22. In terms of profitability, LH's ROE is +0.12%, compared to XGN's ROE of -1.22%. Regarding short-term risk, LH is less volatile compared to XGN. This indicates lower risk in terms of short-term price fluctuations for LH.Check XGN's competition here
Biodesix, Inc. (NASDAQ: BDSX)
LH vs BDSX Comparison October 2026
Labcorp Holdings Inc. (NYSE: LH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LH stands at 26.8B. In comparison, BDSX has a market cap of 173.1M. Regarding current trading prices, LH is priced at $329.90 on the NYSE, while BDSX trades at $21.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LH currently has a P/E ratio of 19.58, whereas BDSX's P/E ratio is -6.71. In terms of profitability, LH's ROE is +0.12%, compared to BDSX's ROE of -7.88%. Regarding short-term risk, LH is less volatile compared to BDSX. This indicates lower risk in terms of short-term price fluctuations for LH.Check BDSX's competition here
Genetron Holdings Limited (NASDAQ: GTH)
LH vs GTH Comparison October 2026
Labcorp Holdings Inc. (NYSE: LH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LH stands at 26.8B. In comparison, GTH has a market cap of 127.3M. Regarding current trading prices, LH is priced at $329.90 on the NYSE, while GTH trades at $4.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LH currently has a P/E ratio of 19.58, whereas GTH's P/E ratio is -1.11. In terms of profitability, LH's ROE is +0.12%, compared to GTH's ROE of -1.01%. Regarding short-term risk, LH is more volatile compared to GTH. This indicates higher risk in terms of short-term price fluctuations for LH.Check GTH's competition here
Genetic Technologies Limited (NASDAQ: GENE)
LH vs GENE Comparison October 2026
Labcorp Holdings Inc. (NYSE: LH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LH stands at 26.8B. In comparison, GENE has a market cap of 111.2M. Regarding current trading prices, LH is priced at $329.90 on the NYSE, while GENE trades at $0.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LH currently has a P/E ratio of 19.58, whereas GENE's P/E ratio is -38.25. In terms of profitability, LH's ROE is +0.12%, compared to GENE's ROE of -1.85%. Regarding short-term risk, LH is more volatile compared to GENE. This indicates higher risk in terms of short-term price fluctuations for LH.Check GENE's competition here
Freenome, Inc. (NASDAQ: FRNM)
LH vs FRNM Comparison October 2026
Labcorp Holdings Inc. (NYSE: LH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LH stands at 26.8B. In comparison, FRNM has a market cap of 103.8M. Regarding current trading prices, LH is priced at $329.90 on the NYSE, while FRNM trades at $12.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LH currently has a P/E ratio of 19.58, whereas FRNM's P/E ratio is N/A. In terms of profitability, LH's ROE is +0.12%, compared to FRNM's ROE of N/A. Regarding short-term risk, LH is less volatile compared to FRNM. This indicates lower risk in terms of short-term price fluctuations for LH.Check FRNM's competition here
Insight Molecular Diagnostics Inc. (NASDAQ: IMDX)
LH vs IMDX Comparison October 2026
Labcorp Holdings Inc. (NYSE: LH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LH stands at 26.8B. In comparison, IMDX has a market cap of 98.2M. Regarding current trading prices, LH is priced at $329.90 on the NYSE, while IMDX trades at $3.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LH currently has a P/E ratio of 19.58, whereas IMDX's P/E ratio is -2.01. In terms of profitability, LH's ROE is +0.12%, compared to IMDX's ROE of +2.72%. Regarding short-term risk, LH is less volatile compared to IMDX. This indicates lower risk in terms of short-term price fluctuations for LH.Check IMDX's competition here
Precipio, Inc. (NASDAQ: PRPO)
LH vs PRPO Comparison October 2026
Labcorp Holdings Inc. (NYSE: LH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LH stands at 26.8B. In comparison, PRPO has a market cap of 35M. Regarding current trading prices, LH is priced at $329.90 on the NYSE, while PRPO trades at $19.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LH currently has a P/E ratio of 19.58, whereas PRPO's P/E ratio is -30.08. In terms of profitability, LH's ROE is +0.12%, compared to PRPO's ROE of -0.08%. Regarding short-term risk, LH is less volatile compared to PRPO. This indicates lower risk in terms of short-term price fluctuations for LH.Check PRPO's competition here
Akumin Inc. (NASDAQ: AKU)
LH vs AKU Comparison October 2026
Labcorp Holdings Inc. (NYSE: LH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LH stands at 26.8B. In comparison, AKU has a market cap of 26.3M. Regarding current trading prices, LH is priced at $329.90 on the NYSE, while AKU trades at $0.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LH currently has a P/E ratio of 19.58, whereas AKU's P/E ratio is -0.13. In terms of profitability, LH's ROE is +0.12%, compared to AKU's ROE of -5.32%. Regarding short-term risk, LH is less volatile compared to AKU. This indicates lower risk in terms of short-term price fluctuations for LH.Check AKU's competition here
Quantum Cyber N.V. (NASDAQ: QUCY)
LH vs QUCY Comparison October 2026
Labcorp Holdings Inc. (NYSE: LH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LH stands at 26.8B. In comparison, QUCY has a market cap of 19.4M. Regarding current trading prices, LH is priced at $329.90 on the NYSE, while QUCY trades at $0.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LH currently has a P/E ratio of 19.58, whereas QUCY's P/E ratio is -0.04. In terms of profitability, LH's ROE is +0.12%, compared to QUCY's ROE of -3.65%. Regarding short-term risk, LH is less volatile compared to QUCY. This indicates lower risk in terms of short-term price fluctuations for LH.Check QUCY's competition here
MDxHealth S.A. (NASDAQ: MDXH)
LH vs MDXH Comparison October 2026
Labcorp Holdings Inc. (NYSE: LH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LH stands at 26.8B. In comparison, MDXH has a market cap of 18.6M. Regarding current trading prices, LH is priced at $329.90 on the NYSE, while MDXH trades at $0.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LH currently has a P/E ratio of 19.58, whereas MDXH's P/E ratio is -0.27. In terms of profitability, LH's ROE is +0.12%, compared to MDXH's ROE of +1.43%. Regarding short-term risk, LH is less volatile compared to MDXH. This indicates lower risk in terms of short-term price fluctuations for LH.Check MDXH's competition here
bioAffinity Technologies, Inc. (NASDAQ: BIAF)
LH vs BIAF Comparison October 2026
Labcorp Holdings Inc. (NYSE: LH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LH stands at 26.8B. In comparison, BIAF has a market cap of 17.8M. Regarding current trading prices, LH is priced at $329.90 on the NYSE, while BIAF trades at $2.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LH currently has a P/E ratio of 19.58, whereas BIAF's P/E ratio is -0.33. In terms of profitability, LH's ROE is +0.12%, compared to BIAF's ROE of -2.57%. Regarding short-term risk, LH is less volatile compared to BIAF. This indicates lower risk in terms of short-term price fluctuations for LH.Check BIAF's competition here
Chembio Diagnostics, Inc. (NASDAQ: CEMI)
LH vs CEMI Comparison October 2026
Labcorp Holdings Inc. (NYSE: LH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LH stands at 26.8B. In comparison, CEMI has a market cap of 16.7M. Regarding current trading prices, LH is priced at $329.90 on the NYSE, while CEMI trades at $0.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LH currently has a P/E ratio of 19.58, whereas CEMI's P/E ratio is -0.63. In terms of profitability, LH's ROE is +0.12%, compared to CEMI's ROE of -0.89%. Regarding short-term risk, LH is more volatile compared to CEMI. This indicates higher risk in terms of short-term price fluctuations for LH.Check CEMI's competition here
Enzo Biochem, Inc. (NYSE: ENZ)
LH vs ENZ Comparison October 2026
Labcorp Holdings Inc. (NYSE: LH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LH stands at 26.8B. In comparison, ENZ has a market cap of 16.4M. Regarding current trading prices, LH is priced at $329.90 on the NYSE, while ENZ trades at $0.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LH currently has a P/E ratio of 19.58, whereas ENZ's P/E ratio is -2.24. In terms of profitability, LH's ROE is +0.12%, compared to ENZ's ROE of -0.39%. Regarding short-term risk, LH is less volatile compared to ENZ. This indicates lower risk in terms of short-term price fluctuations for LH.Check ENZ's competition here
Psychemedics Corporation (NASDAQ: PMD)
LH vs PMD Comparison October 2026
Labcorp Holdings Inc. (NYSE: LH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LH stands at 26.8B. In comparison, PMD has a market cap of 15.6M. Regarding current trading prices, LH is priced at $329.90 on the NYSE, while PMD trades at $2.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LH currently has a P/E ratio of 19.58, whereas PMD's P/E ratio is -5.24. In terms of profitability, LH's ROE is +0.12%, compared to PMD's ROE of -0.32%. Regarding short-term risk, LH is more volatile compared to PMD. This indicates higher risk in terms of short-term price fluctuations for LH.Check PMD's competition here
23andMe Holding Co. (NASDAQ: ME)
LH vs ME Comparison October 2026
Labcorp Holdings Inc. (NYSE: LH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LH stands at 26.8B. In comparison, ME has a market cap of 15.3M. Regarding current trading prices, LH is priced at $329.90 on the NYSE, while ME trades at $0.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LH currently has a P/E ratio of 19.58, whereas ME's P/E ratio is -0.03. In terms of profitability, LH's ROE is +0.12%, compared to ME's ROE of -3.47%. Regarding short-term risk, LH is more volatile compared to ME. This indicates higher risk in terms of short-term price fluctuations for LH.Check ME's competition here
Mainz Biomed B.V. (NASDAQ: MYNZ)
LH vs MYNZ Comparison October 2026
Labcorp Holdings Inc. (NYSE: LH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LH stands at 26.8B. In comparison, MYNZ has a market cap of 14.7M. Regarding current trading prices, LH is priced at $329.90 on the NYSE, while MYNZ trades at $3.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LH currently has a P/E ratio of 19.58, whereas MYNZ's P/E ratio is -1.33. In terms of profitability, LH's ROE is +0.12%, compared to MYNZ's ROE of -1.80%. Regarding short-term risk, LH is less volatile compared to MYNZ. This indicates lower risk in terms of short-term price fluctuations for LH.Check MYNZ's competition here
Burning Rock Biotech Limited (NASDAQ: BNR)
LH vs BNR Comparison October 2026
Labcorp Holdings Inc. (NYSE: LH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LH stands at 26.8B. In comparison, BNR has a market cap of 11.8M. Regarding current trading prices, LH is priced at $329.90 on the NYSE, while BNR trades at $11.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LH currently has a P/E ratio of 19.58, whereas BNR's P/E ratio is -12.82. In terms of profitability, LH's ROE is +0.12%, compared to BNR's ROE of -0.13%. Regarding short-term risk, LH is less volatile compared to BNR. This indicates lower risk in terms of short-term price fluctuations for LH.Check BNR's competition here
Check-Cap Ltd. (NASDAQ: CHEK)
LH vs CHEK Comparison October 2026
Labcorp Holdings Inc. (NYSE: LH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LH stands at 26.8B. In comparison, CHEK has a market cap of 10.9M. Regarding current trading prices, LH is priced at $329.90 on the NYSE, while CHEK trades at $1.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LH currently has a P/E ratio of 19.58, whereas CHEK's P/E ratio is -0.43. In terms of profitability, LH's ROE is +0.12%, compared to CHEK's ROE of -2.26%. Regarding short-term risk, LH is less volatile compared to CHEK. This indicates lower risk in terms of short-term price fluctuations for LH.Check CHEK's competition here
Centogene N.V. (NASDAQ: CNTG)
LH vs CNTG Comparison October 2026
Labcorp Holdings Inc. (NYSE: LH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LH stands at 26.8B. In comparison, CNTG has a market cap of 9.4M. Regarding current trading prices, LH is priced at $329.90 on the NYSE, while CNTG trades at $0.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LH currently has a P/E ratio of 19.58, whereas CNTG's P/E ratio is -0.23. In terms of profitability, LH's ROE is +0.12%, compared to CNTG's ROE of +3.98%. Regarding short-term risk, LH is more volatile compared to CNTG. This indicates higher risk in terms of short-term price fluctuations for LH.Check CNTG's competition here
bioAffinity Technologies, Inc. (NASDAQ: BIAFW)
LH vs BIAFW Comparison October 2026
Labcorp Holdings Inc. (NYSE: LH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LH stands at 26.8B. In comparison, BIAFW has a market cap of 7.8M. Regarding current trading prices, LH is priced at $329.90 on the NYSE, while BIAFW trades at $0.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LH currently has a P/E ratio of 19.58, whereas BIAFW's P/E ratio is 0.83. In terms of profitability, LH's ROE is +0.12%, compared to BIAFW's ROE of -2.57%. Regarding short-term risk, LH is less volatile compared to BIAFW. This indicates lower risk in terms of short-term price fluctuations for LH.Check BIAFW's competition here
ENDRA Life Sciences Inc. (NASDAQ: NDRA)
LH vs NDRA Comparison October 2026
Labcorp Holdings Inc. (NYSE: LH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LH stands at 26.8B. In comparison, NDRA has a market cap of 7.3M. Regarding current trading prices, LH is priced at $329.90 on the NYSE, while NDRA trades at $4.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LH currently has a P/E ratio of 19.58, whereas NDRA's P/E ratio is -0.73. In terms of profitability, LH's ROE is +0.12%, compared to NDRA's ROE of -2.25%. Regarding short-term risk, LH is less volatile compared to NDRA. This indicates lower risk in terms of short-term price fluctuations for LH.Check NDRA's competition here
Applied DNA Sciences, Inc. (NASDAQ: APDN)
LH vs APDN Comparison October 2026
Labcorp Holdings Inc. (NYSE: LH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LH stands at 26.8B. In comparison, APDN has a market cap of 7.3M. Regarding current trading prices, LH is priced at $329.90 on the NYSE, while APDN trades at $5.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LH currently has a P/E ratio of 19.58, whereas APDN's P/E ratio is -0.10. In terms of profitability, LH's ROE is +0.12%, compared to APDN's ROE of -7.23%. Regarding short-term risk, LH is less volatile compared to APDN. This indicates lower risk in terms of short-term price fluctuations for LH.Check APDN's competition here
Invitae Corporation (NYSE: NVTA)
LH vs NVTA Comparison October 2026
Labcorp Holdings Inc. (NYSE: LH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LH stands at 26.8B. In comparison, NVTA has a market cap of 5.4M. Regarding current trading prices, LH is priced at $329.90 on the NYSE, while NVTA trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LH currently has a P/E ratio of 19.58, whereas NVTA's P/E ratio is -0.00. In terms of profitability, LH's ROE is +0.12%, compared to NVTA's ROE of -2.02%. Regarding short-term risk, LH is less volatile compared to NVTA. This indicates lower risk in terms of short-term price fluctuations for LH.Check NVTA's competition here
LumiraDx Limited (NASDAQ: LMDXW)
LH vs LMDXW Comparison October 2026
Labcorp Holdings Inc. (NYSE: LH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LH stands at 26.8B. In comparison, LMDXW has a market cap of 5.1M. Regarding current trading prices, LH is priced at $329.90 on the NYSE, while LMDXW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LH currently has a P/E ratio of 19.58, whereas LMDXW's P/E ratio is -0.00. In terms of profitability, LH's ROE is +0.12%, compared to LMDXW's ROE of -15.58%. Regarding short-term risk, LH is less volatile compared to LMDXW. This indicates lower risk in terms of short-term price fluctuations for LH.Check LMDXW's competition here
LumiraDx Limited (NASDAQ: LMDX)
LH vs LMDX Comparison October 2026
Labcorp Holdings Inc. (NYSE: LH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LH stands at 26.8B. In comparison, LMDX has a market cap of 5.1M. Regarding current trading prices, LH is priced at $329.90 on the NYSE, while LMDX trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LH currently has a P/E ratio of 19.58, whereas LMDX's P/E ratio is -0.01. In terms of profitability, LH's ROE is +0.12%, compared to LMDX's ROE of -15.58%. Regarding short-term risk, LH is less volatile compared to LMDX. This indicates lower risk in terms of short-term price fluctuations for LH.Check LMDX's competition here
Advanced Biomed Inc. Common Stock (NASDAQ: ADVB)
LH vs ADVB Comparison October 2026
Labcorp Holdings Inc. (NYSE: LH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LH stands at 26.8B. In comparison, ADVB has a market cap of 4.7M. Regarding current trading prices, LH is priced at $329.90 on the NYSE, while ADVB trades at $2.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LH currently has a P/E ratio of 19.58, whereas ADVB's P/E ratio is -25.73. In terms of profitability, LH's ROE is +0.12%, compared to ADVB's ROE of +1.22%. Regarding short-term risk, LH is less volatile compared to ADVB. This indicates lower risk in terms of short-term price fluctuations for LH.Check ADVB's competition here
DermTech, Inc. (NASDAQ: DMTK)
LH vs DMTK Comparison October 2026
Labcorp Holdings Inc. (NYSE: LH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LH stands at 26.8B. In comparison, DMTK has a market cap of 3.3M. Regarding current trading prices, LH is priced at $329.90 on the NYSE, while DMTK trades at $0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LH currently has a P/E ratio of 19.58, whereas DMTK's P/E ratio is -0.04. In terms of profitability, LH's ROE is +0.12%, compared to DMTK's ROE of -1.06%. Regarding short-term risk, LH is less volatile compared to DMTK. This indicates lower risk in terms of short-term price fluctuations for LH.Check DMTK's competition here
Inotiv, Inc. (NASDAQ: NOTV)
LH vs NOTV Comparison October 2026
Labcorp Holdings Inc. (NYSE: LH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LH stands at 26.8B. In comparison, NOTV has a market cap of 2.8M. Regarding current trading prices, LH is priced at $329.90 on the NYSE, while NOTV trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LH currently has a P/E ratio of 19.58, whereas NOTV's P/E ratio is -0.03. In terms of profitability, LH's ROE is +0.12%, compared to NOTV's ROE of -0.75%. Regarding short-term risk, LH is less volatile compared to NOTV. This indicates lower risk in terms of short-term price fluctuations for LH.Check NOTV's competition here
SeqLL Inc. (NASDAQ: SQL)
LH vs SQL Comparison October 2026
Labcorp Holdings Inc. (NYSE: LH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LH stands at 26.8B. In comparison, SQL has a market cap of 2.5M. Regarding current trading prices, LH is priced at $329.90 on the NYSE, while SQL trades at $6.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LH currently has a P/E ratio of 19.58, whereas SQL's P/E ratio is -0.40. In terms of profitability, LH's ROE is +0.12%, compared to SQL's ROE of -30.46%. Regarding short-term risk, LH is less volatile compared to SQL. This indicates lower risk in terms of short-term price fluctuations for LH.Check SQL's competition here
Aspira Women's Health Inc. (NASDAQ: AWH)
LH vs AWH Comparison October 2026
Labcorp Holdings Inc. (NYSE: LH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LH stands at 26.8B. In comparison, AWH has a market cap of 2.5M. Regarding current trading prices, LH is priced at $329.90 on the NYSE, while AWH trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LH currently has a P/E ratio of 19.58, whereas AWH's P/E ratio is -0.09. In terms of profitability, LH's ROE is +0.12%, compared to AWH's ROE of +1.62%. Regarding short-term risk, LH is more volatile compared to AWH. This indicates higher risk in terms of short-term price fluctuations for LH.Check AWH's competition here
iSpecimen Inc. (NASDAQ: ISPC)
LH vs ISPC Comparison October 2026
Labcorp Holdings Inc. (NYSE: LH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LH stands at 26.8B. In comparison, ISPC has a market cap of 2.1M. Regarding current trading prices, LH is priced at $329.90 on the NYSE, while ISPC trades at $0.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LH currently has a P/E ratio of 19.58, whereas ISPC's P/E ratio is -0.03. In terms of profitability, LH's ROE is +0.12%, compared to ISPC's ROE of -5.24%. Regarding short-term risk, LH is less volatile compared to ISPC. This indicates lower risk in terms of short-term price fluctuations for LH.Check ISPC's competition here
HTG Molecular Diagnostics, Inc. (NASDAQ: HTGM)
LH vs HTGM Comparison October 2026
Labcorp Holdings Inc. (NYSE: LH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LH stands at 26.8B. In comparison, HTGM has a market cap of 1.1M. Regarding current trading prices, LH is priced at $329.90 on the NYSE, while HTGM trades at $0.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LH currently has a P/E ratio of 19.58, whereas HTGM's P/E ratio is -0.03. In terms of profitability, LH's ROE is +0.12%, compared to HTGM's ROE of -2.73%. Regarding short-term risk, LH is more volatile compared to HTGM. This indicates higher risk in terms of short-term price fluctuations for LH.Check HTGM's competition here
Biocept, Inc. (NASDAQ: BIOC)
LH vs BIOC Comparison October 2026
Labcorp Holdings Inc. (NYSE: LH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LH stands at 26.8B. In comparison, BIOC has a market cap of 450.8K. Regarding current trading prices, LH is priced at $329.90 on the NYSE, while BIOC trades at $0.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LH currently has a P/E ratio of 19.58, whereas BIOC's P/E ratio is -0.01. In terms of profitability, LH's ROE is +0.12%, compared to BIOC's ROE of -1.38%. Regarding short-term risk, LH is less volatile compared to BIOC. This indicates lower risk in terms of short-term price fluctuations for LH.Check BIOC's competition here
SeqLL Inc. (NASDAQ: SQLLW)
LH vs SQLLW Comparison October 2026
Labcorp Holdings Inc. (NYSE: LH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LH stands at 26.8B. In comparison, SQLLW has a market cap of 179.6K. Regarding current trading prices, LH is priced at $329.90 on the NYSE, while SQLLW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LH currently has a P/E ratio of 19.58, whereas SQLLW's P/E ratio is -0.00. In terms of profitability, LH's ROE is +0.12%, compared to SQLLW's ROE of -30.46%. Regarding short-term risk, LH is less volatile compared to SQLLW. This indicates lower risk in terms of short-term price fluctuations for LH.Check SQLLW's competition here
GeneDx Holdings Corp. (NASDAQ: WGSWW)
LH vs WGSWW Comparison October 2026
Labcorp Holdings Inc. (NYSE: LH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LH stands at 26.8B. In comparison, WGSWW has a market cap of 5.8K. Regarding current trading prices, LH is priced at $329.90 on the NYSE, while WGSWW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LH currently has a P/E ratio of 19.58, whereas WGSWW's P/E ratio is -0.00. In terms of profitability, LH's ROE is +0.12%, compared to WGSWW's ROE of -0.39%. Regarding short-term risk, LH is more volatile compared to WGSWW. This indicates higher risk in terms of short-term price fluctuations for LH.Check WGSWW's competition here
Ortho Clinical Diagnostics Holdings plc (NASDAQ: OCDX)
LH vs OCDX Comparison October 2026
Labcorp Holdings Inc. (NYSE: LH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LH stands at 26.8B. In comparison, OCDX has a market cap of 0. Regarding current trading prices, LH is priced at $329.90 on the NYSE, while OCDX trades at $17.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LH currently has a P/E ratio of 19.58, whereas OCDX's P/E ratio is -42.28. In terms of profitability, LH's ROE is +0.12%, compared to OCDX's ROE of +0.18%. Regarding short-term risk, LH is less volatile compared to OCDX. This indicates lower risk in terms of short-term price fluctuations for LH.Check OCDX's competition here
Check-Cap Ltd (NASDAQ: CHEKZ)
LH vs CHEKZ Comparison October 2026
Labcorp Holdings Inc. (NYSE: LH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LH stands at 26.8B. In comparison, CHEKZ has a market cap of 0. Regarding current trading prices, LH is priced at $329.90 on the NYSE, while CHEKZ trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LH currently has a P/E ratio of 19.58, whereas CHEKZ's P/E ratio is N/A. In terms of profitability, LH's ROE is +0.12%, compared to CHEKZ's ROE of +4.17%. Regarding short-term risk, LH is less volatile compared to CHEKZ. This indicates lower risk in terms of short-term price fluctuations for LH.Check CHEKZ's competition here
BioNano Genomics, Inc. WT EXP 082123 (NASDAQ: BNGOW)
LH vs BNGOW Comparison October 2026
Labcorp Holdings Inc. (NYSE: LH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LH stands at 26.8B. In comparison, BNGOW has a market cap of 0. Regarding current trading prices, LH is priced at $329.90 on the NYSE, while BNGOW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LH currently has a P/E ratio of 19.58, whereas BNGOW's P/E ratio is N/A. In terms of profitability, LH's ROE is +0.12%, compared to BNGOW's ROE of -0.79%. Regarding short-term risk, LH is less volatile compared to BNGOW. This indicates lower risk in terms of short-term price fluctuations for LH.Check BNGOW's competition here
23andMe Holding Co. (NASDAQ: MEUSW)
LH vs MEUSW Comparison October 2026
Labcorp Holdings Inc. (NYSE: LH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LH stands at 26.8B. In comparison, MEUSW has a market cap of 0. Regarding current trading prices, LH is priced at $329.90 on the NYSE, while MEUSW trades at $1.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LH currently has a P/E ratio of 19.58, whereas MEUSW's P/E ratio is N/A. In terms of profitability, LH's ROE is +0.12%, compared to MEUSW's ROE of -3.47%. Regarding short-term risk, LH is less volatile compared to MEUSW. This indicates lower risk in terms of short-term price fluctuations for LH.Check MEUSW's competition here
Danaher Corporation (NYSE: DHR-PA)
LH vs DHR-PA Comparison October 2026
Labcorp Holdings Inc. (NYSE: LH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LH stands at 26.8B. In comparison, DHR-PA has a market cap of 0. Regarding current trading prices, LH is priced at $329.90 on the NYSE, while DHR-PA trades at $1,841.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LH currently has a P/E ratio of 19.58, whereas DHR-PA's P/E ratio is 233.57. In terms of profitability, LH's ROE is +0.12%, compared to DHR-PA's ROE of +0.08%. Regarding short-term risk, LH is less volatile compared to DHR-PA. This indicates lower risk in terms of short-term price fluctuations for LH.Check DHR-PA's competition here
ENDRA Life Sciences Inc. Warrants (NASDAQ: NDRAW)
LH vs NDRAW Comparison October 2026
Labcorp Holdings Inc. (NYSE: LH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LH stands at 26.8B. In comparison, NDRAW has a market cap of 0. Regarding current trading prices, LH is priced at $329.90 on the NYSE, while NDRAW trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LH currently has a P/E ratio of 19.58, whereas NDRAW's P/E ratio is N/A. In terms of profitability, LH's ROE is +0.12%, compared to NDRAW's ROE of -2.25%. Regarding short-term risk, LH is less volatile compared to NDRAW. This indicates lower risk in terms of short-term price fluctuations for LH.Check NDRAW's competition here
PAREXEL Intl Corp. (NASDAQ: PRXL)
LH vs PRXL Comparison October 2026
Labcorp Holdings Inc. (NYSE: LH) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LH stands at 26.8B. In comparison, PRXL has a market cap of 0. Regarding current trading prices, LH is priced at $329.90 on the NYSE, while PRXL trades at $88.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LH currently has a P/E ratio of 19.58, whereas PRXL's P/E ratio is 42.97. In terms of profitability, LH's ROE is +0.12%, compared to PRXL's ROE of +0.17%. Regarding short-term risk, LH is more volatile compared to PRXL. This indicates higher risk in terms of short-term price fluctuations for LH.Check PRXL's competition here